Malwina Anna Sołtysiak

Dr. Malwina Anna Sołtysiak

2nd Department of Respiratory Medicine, National Tuberculosis and Lung Diseases Research Institute, Warsaw, Mazowieckie, Poland
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2022 in Polish Journal of Environmental Studies
Verified
Journal Article
Open access
ATAgnieszka Tuzimek
Agnieszka Tuzimek
IOIzabela Orzołek
Izabela Orzołek
KPKarolina Paralusz
Karolina Paralusz
MPMichał Przybyszewski
Michał Przybyszewski
Malwina Anna SołtysiakMalwina Anna Sołtysiak
Malwina Anna Sołtysiak
MPMagdalena Paplińska-Goryca
Magdalena Paplińska-Goryca
The Mycobacterium tuberculosis complex (MTBC) consists of species and subspecies that cause tuberculosis (TB) in humans and animals. As all MTBC strains are closely related at the molecular level, the exact distinction between them is not implemented in routine diagnostic techniques but could be used for tracking the zoonotic infection route, identification of drug resistance and epidemiological profiling. This study aimed to analyse the distribution of MTBC species in TB patients in the urban setting of Warsaw (central Poland). A total of 58 clinical isolates derived from patients diagnosed with TB were analysed. All specimens were processed for culture, DNA extraction and PCR. The distribution of species was investigated using GenoType MTBC molecular assay. All TB cases analysed were caused by Mycobacterium tuberculosis. M. tuberculosis appears to be the predominant cause of TB in Warsaw, central Poland, as no cases found of human TB caused by M. bovis or other MTBC strains were found.

7 September 2020 in European Respiratory Journal
Verified
Conference Paper
Closed access
Malwina Anna SołtysiakMalwina Anna Sołtysiak
Malwina Anna Sołtysiak
MPMagdalena Paplińska-Goryca
Magdalena Paplińska-Goryca
KKKatarzyna Koziak
Katarzyna Koziak
RKRafał Krenke
Rafał Krenke
Introduction: β-Escin is a mixture of triterpenoid saponins extracted from the fruit of horse chestnut tree (Aesculus hippocastanum. L). Recent advances in the understanding of β-escin potent anti-inflammatory effects provides rationale for its novel uses beyond the current vascular indications. The active compounds found in chokeberry (Aronia melanocarpa) also exhibit antioxidant activity. The aim of the study was to evaluate the antioxidant and anti-inflammatory effects of β-escin and chokeberry extract used as functional food in healthy tobacco smokers. Methods: We recruited 9 smoking participants who received 10 mg of water soluble β-escin and 5 mg of chokeberry juice concentrate for 2 weeks. Control group included 5 healthy nonsmokers with no escin and chokeberry supplementation. The spirometry and sputum induction were performed in study patients at baseline (V0), after 1 (V1) and 2 weeks (V2) of escin and chokeberry supplementation. In controls, the same procedures were conducted at V0 and V1 time points. The antioxidant capacity, acetaldehyde, IL-6 and IL-8 level were measured in sputum. Results: An elevated baseline IL-6 level (p=0.03) but not IL-8 (p=0.81) or acetaldehyde (p=0.07) levels were found in smokers compared to non-smokers. The decrease in the number of sputum neutrophils was observed after one week of β-escin and chokeberry supplementation (p=0.04). Conclusion: This preliminary study suggested that low dose β-escin and chokeberry supplementation may be associated with significant reduction of airway neutrophil number but no other evaluated biomarkers, further studies are needed.

6 November 2026 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
Malwina Anna SołtysiakMalwina Anna Sołtysiak
Malwina Anna Sołtysiak
PŚPaweł Śliwiński
Paweł Śliwiński
Background and clinical significance: Entrectinib is an effective therapy for ROS1-positive metastatic non-small cell lung cancer (NSCLC), but rare cardiotoxicity can easily be overlooked due to its non-specific presentation. Case presentation: We report the case of a 55-year-old woman with ROS1-positive NSCLC who developed persistent fever and hypotension (85/60 mmHg) after three months of entrectinib, despite achieving excellent tumour regression. Sepsis or neoplastic fever was initially suspected; however, she subsequently developed progressive dyspnoea and acute respiratory failure with rising cardiac biomarkers despite a preserved left ventricular ejection fraction (58%). Multiparametric cardiac magnetic resonance (CMR) findings were consistent with perimyocarditis, and endomyocardial biopsy was not performed. Following drug withdrawal and initiation of therapy for heart failure with preserved ejection fraction (HFpEF) along with colchicine and naproxen for pericardial inflammation, gradual cardiac recovery was achieved, but the tumour rapidly progressed within 13 days (from 22 to 35 mm). Entrectinib was reintroduced at a reduced dose (200 mg daily), yet recurrent cardiopulmonary failure occurred two weeks later, requiring permanent discontinuation. Conclusions: This case highlights that entrectinib-associated perimyocarditis can mimic infection, emphasizing the role of advanced non-invasive cardiac imaging, particularly CMR, in establishing the diagnosis. It underscores the profound therapeutic challenge of balancing the life-prolonging benefits of targeted oncological therapy against severe, recurrent cardiotoxicity.